Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Blood Protein Disorders

ClinicalTrials.gov lists 4,252 trials for Blood Protein Disorders or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 182.

MeSH D001796 Hemic and Lymphatic Diseases C15
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 956 Phase 1/2 Phase 1/2 499 Phase 2 Phase 2 1,298 Phase 2/3 Phase 2/3 39 Phase 3 Phase 3 395 Phase 4 Phase 4 74 Not applicable Not applicable 378 Observational Observational 578 Phase 1 Phase 1 956 Phase 1/2 Phase 1/2 499 Phase 2 Phase 2 1,298 Phase 2/3 Phase 2/3 39 Phase 3 Phase 3 395 Phase 4 Phase 4 74 Not applicable Not applicable 378 Observational Observational 578

Trials per phase (log scale)

2 more sections with rows

23 of the 4,252 trials are tagged with Blood Protein Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Blood Protein Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Blood Protein Disorders trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 11 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 219

1990: 3 trials (Observational 1, Phase 2 2) 1991: 1 trials (Phase 2 1) 1992: 4 trials (Phase 2 2, Phase 1/2 1, Phase 1 1) 1993: 6 trials (Observational 2, Phase 3 1, Phase 2 3) 1994: 6 trials (Phase 3 3, Phase 2 3) 1995: 11 trials (Observational 1, Phase 3 4, Phase 2 4, Phase 1/2 1, Phase 1 1) 1996: 15 trials (Observational 1, Phase 3 4, Phase 2 8, Phase 1 2) 1997: 28 trials (Not applicable 3, Phase 3 5, Phase 2 13, Phase 1/2 2, Phase 1 5) 1998: 53 trials (Not applicable 2, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 32, Phase 1/2 2, Phase 1 9) 1999: 52 trials (Not applicable 4, Phase 3 8, Phase 2 24, Phase 1/2 5, Phase 1 11) 2000: 61 trials (Observational 3, Not applicable 6, Phase 3 14, Phase 2/3 1, Phase 2 23, Phase 1/2 9, Phase 1 5) 2001: 57 trials (Observational 4, Not applicable 7, Phase 4 1, Phase 3 5, Phase 2/3 4, Phase 2 21, Phase 1/2 6, Phase 1 9) 2002: 74 trials (Observational 5, Not applicable 6, Phase 3 12, Phase 2/3 1, Phase 2 31, Phase 1/2 8, Phase 1 11) 2003: 75 trials (Observational 3, Not applicable 8, Phase 4 1, Phase 3 16, Phase 2/3 2, Phase 2 18, Phase 1/2 10, Phase 1 17) 2004: 103 trials (Observational 5, Not applicable 7, Phase 4 3, Phase 3 10, Phase 2/3 2, Phase 2 45, Phase 1/2 13, Phase 1 18) 2005: 122 trials (Observational 10, Not applicable 8, Phase 3 14, Phase 2 50, Phase 1/2 16, Phase 1 24) 2006: 128 trials (Observational 14, Not applicable 6, Phase 4 2, Phase 3 21, Phase 2 47, Phase 1/2 16, Phase 1 22) 2007: 131 trials (Other 1, Observational 8, Not applicable 8, Phase 4 4, Phase 3 12, Phase 2/3 1, Phase 2 50, Phase 1/2 16, Phase 1 31) 2008: 162 trials (Observational 20, Not applicable 7, Phase 4 1, Phase 3 18, Phase 2/3 2, Phase 2 56, Phase 1/2 16, Phase 1 42) 2009: 129 trials (Other 2, Observational 17, Not applicable 6, Phase 3 16, Phase 2/3 4, Phase 2 39, Phase 1/2 19, Phase 1 26) 2010: 159 trials (Observational 22, Not applicable 11, Phase 4 4, Phase 3 12, Phase 2 55, Phase 1/2 27, Phase 1 28) 2011: 131 trials (Observational 15, Not applicable 10, Phase 4 3, Phase 3 13, Phase 2 43, Phase 1/2 22, Phase 1 25) 2012: 149 trials (Observational 16, Not applicable 8, Phase 4 1, Phase 3 8, Phase 2 58, Phase 1/2 20, Phase 1 38) 2013: 137 trials (Observational 21, Not applicable 10, Phase 4 1, Phase 3 14, Phase 2/3 1, Phase 2 42, Phase 1/2 21, Phase 1 27) 2014: 156 trials (Observational 15, Not applicable 10, Phase 4 2, Phase 3 13, Phase 2/3 2, Phase 2 46, Phase 1/2 20, Phase 1 48) 2015: 150 trials (Observational 20, Not applicable 8, Phase 4 2, Phase 3 13, Phase 2/3 1, Phase 2 56, Phase 1/2 15, Phase 1 35) 2016: 159 trials (Observational 24, Not applicable 12, Phase 4 7, Phase 3 9, Phase 2/3 1, Phase 2 58, Phase 1/2 18, Phase 1 30) 2017: 170 trials (Observational 25, Not applicable 7, Phase 4 2, Phase 3 15, Phase 2/3 1, Phase 2 51, Phase 1/2 23, Phase 1 46) 2018: 158 trials (Observational 26, Not applicable 11, Phase 4 2, Phase 3 8, Phase 2/3 1, Phase 2 56, Phase 1/2 16, Phase 1 38) 2019: 189 trials (Observational 25, Not applicable 11, Phase 4 6, Phase 3 17, Phase 2/3 1, Phase 2 50, Phase 1/2 29, Phase 1 50) 2020: 172 trials (Observational 38, Not applicable 23, Phase 4 3, Phase 3 14, Phase 2/3 2, Phase 2 33, Phase 1/2 11, Phase 1 48) 2021: 219 trials (Observational 35, Not applicable 21, Phase 4 2, Phase 3 12, Phase 2 62, Phase 1/2 25, Phase 1 62) 2022: 213 trials (Observational 43, Not applicable 31, Phase 4 7, Phase 3 14, Phase 2/3 1, Phase 2 43, Phase 1/2 22, Phase 1 52) 2023: 211 trials (Observational 47, Not applicable 33, Phase 4 2, Phase 3 12, Phase 2/3 2, Phase 2 42, Phase 1/2 31, Phase 1 42) 2024: 193 trials (Observational 42, Not applicable 25, Phase 4 4, Phase 3 16, Phase 2 37, Phase 1/2 17, Phase 1 52) 2025: 189 trials (Observational 34, Not applicable 36, Phase 4 5, Phase 3 12, Phase 2/3 2, Phase 2 45, Phase 1/2 16, Phase 1 39)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 211
2025 189
2024 193
2023 211
2022 213
2021 219
2020 172
2019 189
2018 158
2017 170

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 230 trials starting in 2026 and about 210 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 521 trials still running at the 2026-10-09 snapshot; registered median of 39 months across 2,636 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Blood Protein Disorders trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 956
Phase 1/2 499
Phase 2 1,298
Phase 2/3 39
Phase 3 395
Phase 4 74
Not applicable 378
Observational 578
Expanded access 34
Unknown 1

How many Blood Protein Disorders trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 169
Recruiting 580
Enrolling by invitation 15
Active, not recruiting 342
Available 6

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Blood Protein Disorders trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 182
Celgene 93
Janssen Research & Development, LLC 67
Amgen 42
GlaxoSmithKline 41

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Blood Protein Disorders? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 333
Melphalan 230
POMALIDOMIDE 183
RITUXIMAB 113
THALIDOMIDE 105

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 729
Bortezomib SC 412
X: Lenalidomide 406
SQ Fludarabine 215
Daratumumab SC 202

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Blood Protein Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 4,653 321
Pyrexia 1,609 221
Thrombocytopenia 1,342 180
Febrile neutropenia 1,277 239
Sepsis 1,263 305

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Blood Protein Disorders? (8)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Understanding and interpreting serum protein electrophoresis. American family physician 2005 Yes
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. Blood 1986 Yes
Collaborative US-USSR study on the prevalence of dyslipoproteinemias and ischemic heart disease in American and Soviet populations. Prepared by the US-USSR Steering Committee for Problem Area 1: the pathogenesis of atherosclerosis. The American journal of cardiology 1977 Yes
Interpretation of serum calcium in patients with abnormal serum proteins. British medical journal 1973 Yes
NET CATION EQUIVALENCY ('BASE BINDING POWER') OF THE PLASMA PROTEINS. Acta medica Scandinavica 1964 Yes

Showing 5 of 8 publications.

Start your 14-day trial Email me all 8 publications as a PDF

Sub-conditions in MeSH (8)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages